Affiliation:
1. Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research; Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Shanghai 201203 People's Republic of China
Funder
National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”
National Natural Science Foundation of China
Knowledge Innovation Program of Chinese Academy of Sciences
Reference39 articles.
1. The two TORCs and Akt;Bhaskar;Dev. Cell,2007
2. Carcinogenesis of PIK3CA;German;Hereditary Cancer Clin Pract,2013
3. Rapamycin passes the torch: a new generation of mTOR inhibitors;Benjamin;Nat Rev Drug Discov,2011
4. MECHCATIE E. FDA Approves mTOR Inhibitor Everolimus for Breast Cancer http://wwwinternalmedicinenewscom/specialty-focus/oncology-hematology/single-article-page/fda-approves-mtor-inhibitor-everolimus-for-breast-cancerhtml
5. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma;A;British journal of cancer,2012
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献